We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Atomo's Blood Test Unveiled at 2014 AACC; Takes Top Award in NY

By LabMedica International staff writers
Posted on 01 Aug 2014
Print article
Atomo Diagnostics (Melbourne, Australia) showcased integrated rapid blood test device to the USA market at the 2014 AACC Annual Meeting and Clinical Lab Expo, following a successful presentation at the 20th International AIDS Conference 2014 in Melbourne (Australia). The AtomoRapid all-in-one blood test can accommodate test strips for a wide variety of conditions from celiac disease and allergy through to infectious diseases such as malaria and human immunodeficiency virus (HIV).

The device delivers better clinical outcomes for patients and health care providers by enabling simpler, safer, and more accurate testing in the field or at home.

At AIDS 2014, Atomo Diagnostics participated in a conference session organized by the World Health Organization (WHO; Basel, Switzerland). The session focused on opportunities and challenges facing self-testing and a debate about real world situations. The AtomoRapid all-in-one blood test, which is half the size of an iPhone, has been deployed in South Africa for HIV and malaria testing, and clinical activities are in process in the EU and in planning in Asia and the USA.

Former ResMed executive and Atomo Diagnostics’ founder and CEO John Kelly MSc, BEng, comments: ”We have started with HIV and malaria because that was where false negatives and false positives from other existing ‘bits in a box’ products, which were sometimes greater than 10% when used in the field, were having the most significant impact on individuals.”

AtomoRapid HIV could play a significant role in supporting the Australian Government’s initiative to lift restrictions on home HIV testing. Around 30% of Australians with HIV are diagnosed well after they should have started treatment to restore their damaged immune system, according to the latest Annual HIV Surveillance report from the UNSW’s Kirby Institute (Sydney, Australia) Annual Symposium.

John Kelly adds, "We have seen from our work with the Desmond Tutu HIV Foundation in South Africa that if you want to be accepted as an at-home test you need an integrated intuitive solution that reduces test errors." Kelly was inspired to find a better way to test blood when his daughter developed a childhood disease requiring regular blood draws for diagnostic tests.

Given its ease of use and simplicity, AtomoRapid has the ability to materially improve both the uptake and reliability of testing in the community and at home. The company is currently implementing its plans to launch the product in Australia, the US, and Europe for both professional and at home use.

Over 100 million rapid HIV tests are bought each year globally, and Atomo Diagnostics is leading the transition to more user friendly all-in-one solution with its AtomoRapid innovation.

AtomoRapid took the top international medical technology award last month in New York at the Medical Design Excellence Awards and has been given a number of other important honors.

Related Links:

Atomo Diagnostics
World Health Organization
Kirby Institute


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.